Abivax share falls below €81.45, RSI in extreme oversold territory
The biotech company specializing in inflammatory diseases extends its decline this Monday, against the trend of an SBF 120 that remains stable during the session. The decline is part of a downward sequence that has erased more than 20% of value over the month, bringing the stock back to levels not seen in several months.
A marked decline that keeps Abivax among the most neglected stocks in the SBF 120
Abivax loses 2.44% to €79.90 during the session, while the SBF 120 shows virtually no change (+0.11%). The stock ranks among the laggards of the index, with a position among the three most underperforming values of the session. Over one week, the decline reaches 12.2%, and over one month, the loss exceeds 20%, reflecting sustained selling pressure since the presentation of half-year results on September 21.
Over three months, however, the decline remains more contained at 5.44%, and over one year, the stock still retains 13.66% in gains, illustrating the magnitude of the recent underperformance relative to long-term momentum. The VIX meanwhile climbs to 16.29 on Monday, compared to 14.87 at the last close, signaling increased market tension that does not favor high-risk biotech stocks.
A degraded technical setup and still significant short positions
The RSI of Abivax has fallen to 25, in extreme oversold territory, following a week of continuous pressure. Yet this signal is accompanied by no inflection: the price remains well below its three moving averages, with a gap of 15.10% below the 20-day MA at €94.11, and approximately 22% below the 50-day MA (€102.58) and the 200-day MA (€102.33). The stock is now trading well below the support threshold at €81.45, which it had broken through to the downside in previous sessions, opening the way to recently untested levels, while resistance at €105.90 remains very distant.
On the short position front, according to reviewed disclosures, four funds cumulate 4.47% of capital sold short (latest disclosure on September 24, 2026), in sharp reduction from the 7.05% recorded thirty days ago (a decrease of -2.58 percentage points). This decline in cumulative short positions indicates that some funds have reduced their bearish exposure, though the remaining level is far from negligible: 4.47% of capital represents a significant presence of funds positioned to the downside, to be monitored over time. The consensus of analysts on the stock remains worth monitoring in this context of prolonged decline.
